#CF370 - Twitter Hashtag

about 4 years ago

DLA #CF370 center stage w/ #ECCMID2022 oral presentation. Data demonstrated⬆️efficacy in rabbit model of hard-to-treat extensively-drug-resistant strain of P. aeruginosa & CF-370 ability to avoid #AMR & suppress #antibioticresistance. Kudos to $CFRX team! https://t.co/CHgO2l73Md

ContraFectCorp's tweet photo. DLA #CF370 center stage w/ #ECCMID2022 oral presentation. Data demonstrated⬆️efficacy in rabbit model of hard-to-treat extensively-drug-resistant strain of P. aeruginosa & CF-370 ability to avoid #AMR & suppress #antibioticresistance. Kudos to $CFRX team!
https://t.co/CHgO2l73Md https://t.co/ZhXCC4mXRi

0

5

1

0

ContraFect @ContraFectCorp

about 4 years ago

Big lineup @ #ECCMID2022: $CFRX selected for oral presentation & six posters. New data will highlight lead candidate #exebacase in #PH3 superiority study, #CF370 our engineered lysin, & lead compounds in our amurin peptide program. See you live or online! https://t.co/xh7XU7HsDo

ContraFectCorp's tweet photo. Big lineup @ #ECCMID2022: $CFRX selected for oral presentation & six posters. New data will highlight lead candidate #exebacase in #PH3 superiority study, #CF370 our engineered lysin, & lead compounds in our amurin peptide program. See you live or online!
https://t.co/xh7XU7HsDo https://t.co/2RcTMCsRU0

1

5

2

0

ContraFect @ContraFectCorp

almost 5 years ago

Check out our $CFRX CEO interview: Roger Pomerantz discusses engineered lysins, #exebacase's role as new modality causing a paradigm shift as an #antimicrobial, & ContraFect's next candidate #CF370 targeting #PseudomonasAeruginosa. Great recap of our mission and clinical focus!

BioTuesdays @BioTuesdays

almost 5 years ago

This weeks feature - In a bid to counter the next great health crisis, ContraFect is in late-stage development of a new modality to treat life-threatening and antibiotic-resistant infections, using direct lytic agents (DLAs). $CFRX https://t.co/Cn5qudFb7l

0

2

0

3

1

0

ContraFect @ContraFectCorp

almost 5 years ago

New data @ESCMID #ECCMID2021: #exebacase, #PH3 w/ Breakthrough Therapy Designation for #MRSA, has potential to treat Staph bone & joint infections. #CF370 1st engineered lysin shows activity against #MultiDrugResistant #GramNeg. $CFRX programs move forward https://t.co/1bo3h1Xxkn

ContraFectCorp's tweet photo. New data @ESCMID #ECCMID2021: #exebacase, #PH3 w/ Breakthrough Therapy Designation for #MRSA, has potential to treat Staph bone & joint infections. #CF370 1st engineered lysin shows activity against #MultiDrugResistant #GramNeg. $CFRX programs move forward
https://t.co/1bo3h1Xxkn https://t.co/PDnXgkBCSi

0

10

1

0

ContraFect @ContraFectCorp

about 5 years ago

Important IP news:@uspto issued $CFRX patent for #CF370, our 2nd potential therapeutic candidate. Patent titled Lysin-Antimicrobial Peptide (AMP) Polypeptide Constructs, Lysins, Isolated Polynucleotides, part of our #DLA portfolio, #Gramnegative infections https://t.co/v7BcQB36dI

ContraFectCorp's tweet photo. Important IP news:@uspto issued $CFRX patent for #CF370, our 2nd potential therapeutic candidate. Patent titled Lysin-Antimicrobial Peptide (AMP) Polypeptide Constructs, Lysins, Isolated Polynucleotides, part of our #DLA portfolio, #Gramnegative infections
https://t.co/v7BcQB36dI https://t.co/tB9qRseC2L

0

7

5

0

ContraFect @ContraFectCorp

over 5 years ago

Along w/@BARDA $, more news @ $CFRX: closed public offering of common stock - net proceeds $57.5M. Intend to fund: #exebacase #PH3, PH 1/2 of exebacase for pts w/ chronic post-op #Saureus prosthetic joint infections + #IND activity w/ PH 1a/1b #CF370 trial https://t.co/qlszEuOR8q

ContraFectCorp's tweet photo. Along w/@BARDA $, more news @ $CFRX: closed public offering of common stock - net proceeds $57.5M. Intend to fund: #exebacase #PH3, PH 1/2 of exebacase for pts w/ chronic post-op #Saureus prosthetic joint infections + #IND activity w/ PH 1a/1b #CF370 trial
https://t.co/qlszEuOR8q https://t.co/EZAwJxinAQ

1

10

2

0

ContraFect @ContraFectCorp

about 6 years ago

During #COVID19 we move forward w/ heightened sense of purpose: published 4 abstracts @ESCMID to advance new antibacterial modalities: novel native lysins, engineered lysins, and #amurinpeptides. We fight #antibioticresistance every day #exebacase #CF370 https://t.co/tZDdF5JPJK

ContraFectCorp's tweet photo. During #COVID19 we move forward w/ heightened sense of purpose: published 4 abstracts @ESCMID to advance new antibacterial modalities: novel native lysins, engineered lysins, and #amurinpeptides. We fight #antibioticresistance every day #exebacase #CF370
https://t.co/tZDdF5JPJK https://t.co/EGtyHemqlt

0

8

0

Motus Commercials DAF 🇬🇧 @MotusDAF

over 6 years ago

⭐EX DEMO #FORSALE⭐ #DAF #CF370 FAN Rear Steer Day Cab - 26,000KG GVW - Traxon Auto 12-Speed Gearbox - Less than 10,000KM - Reg June 19 Interested? Get in touch! 📧 [email protected] [email protected] #DAFCF #truck #winningwednesday

MotusDAF's tweet photo. ⭐EX DEMO #FORSALE⭐

#DAF #CF370 FAN Rear Steer Day Cab

- 26,000KG GVW
- Traxon Auto 12-Speed Gearbox
- Less than 10,000KM
- Reg June 19

Interested? Get in touch! 📧
ian.wakefield@motuscommercials.co.uk
chris.cooke@motuscommercials.co.uk

#DAFCF #truck #winningwednesday https://t.co/hz5aZjOPpk

0

5

1

0

Top Tweets for #CF370

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users